Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Empagliflozin for Kidney Transplant Complications
Recruiting0 awardsPhase 2
Durham, North Carolina
This trial is testing a medication called empagliflozin, which helps lower blood sugar, in kidney transplant patients. The study includes patients with and without type 2 diabetes to see if the medication can improve their health. Empagliflozin works by helping the kidneys remove extra sugar from the blood through urine. This medication has been shown to significantly reduce blood glucose levels and is well tolerated in patients with type 2 diabetes.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service